[Antithrombotic therapy in atrial arrhythmia]

Area of Science:

• Cardiology
• Pharmacology

Context:

• Atrial arrhythmias pose a significant risk of thrombo-embolic events, particularly cerebrovascular accidents (stroke).
• Oral anticoagulants are proven effective in reducing stroke risk, outperforming anti-platelet drugs.
• Vitamin K antagonists (e.g., warfarin) have a notable annual hemorrhage risk (around 5%), limiting their use in elderly or high-risk patients.

Purpose:

• To review the efficacy and risks of oral anticoagulants for preventing stroke in atrial arrhythmias.
• To explore alternative therapeutic options, such as direct anti-thrombin agents, for patients where warfarin is contraindicated or poses excessive risk.
• To discuss the management of thrombo-embolic risk associated with cardioversion in atrial arrhythmia patients.

Summary:

• Oral anticoagulants significantly reduce cerebrovascular accident risk in atrial arrhythmias compared to anti-platelet agents.
• The risk of serious hemorrhage with warfarin restricts its use, leading to under-prescription in the elderly.
• Direct anti-thrombin agents like ximelagatran present promising alternatives, and anticoagulant therapy is crucial for managing cardioversion risks.

Impact:

• Highlights the clinical challenge of balancing stroke prevention with bleeding risk in atrial arrhythmia management.
• Underscores the need for safer anticoagulant alternatives, particularly for elderly and high-risk populations.
• Informs clinical practice regarding the appropriate use of anticoagulation and the potential of novel therapeutics in managing atrial arrhythmias and associated thrombo-embolic complications.